Abstract

Most risk is linked to research into and the development of new drug entities; about 80% of all drugs fail clinical trials because of either toxicity or efficacy issues. Closely associated with these problems are the increasing costs of clinical trials, which will make it more difficult for biotech companies to take products through to clinical proof-of-concept in Phase II. What is the solution?

Copyright: © IQVIA 2018